XHKG
9955
Market cap44mUSD
Jul 09, Last price
0.54HKD
1D
-5.26%
1Q
-22.86%
IPO
-98.00%
Name
ClouDr Group Ltd
Chart & Performance
P/E
—
P/S
0.19
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.43%
Rev. gr., 5y
14.11%
Revenues
1.62b
-53.47%
Net income
-924m
L+78.96%
CFO
82m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ClouDr Group Limited operates as an investment holding company, providing a diverse range of services within the healthcare sector. The firm supplies hospitals and pharmacies with crucial medical products, including devices like blood glucose meters and vital sign monitors, glucose testing strips, and both over-the-counter and prescription drugs. In addition to physical goods, ClouDr delivers software-as-a-service (SaaS) platforms tailored for healthcare facilities and pharmacies, while also offering digital marketing solutions to pharmaceutical companies. Furthermore, the company facilitates the management of chronic conditions through real-time online consultations, digital health monitoring, and remote prescription and ordering services. Established in 2014, ClouDr Group Limited maintains its primary corporate office in Hangzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||